MA40814A1 - Compositions pharmaceutiques pour thérapie combinée - Google Patents

Compositions pharmaceutiques pour thérapie combinée

Info

Publication number
MA40814A1
MA40814A1 MA40814A MA40814A MA40814A1 MA 40814 A1 MA40814 A1 MA 40814A1 MA 40814 A MA40814 A MA 40814A MA 40814 A MA40814 A MA 40814A MA 40814 A1 MA40814 A1 MA 40814A1
Authority
MA
Morocco
Prior art keywords
agonist
ppar
pharmaceutical compositions
combination therapy
combination
Prior art date
Application number
MA40814A
Other languages
English (en)
Inventor
Mark Pruzanski
Luciano Adorini
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40814(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MA40814A1 publication Critical patent/MA40814A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant une combinaison d'un agoniste de fxr et au moins un agent réducteur de lipides (par exemple, agoniste de ppar-alpha agoniste de ppar-delta, agoniste de ppar-alpha et double delta et/ou statine). La présente invention concerne également l'utilisation de la combinaison pour le traitement ou la prévention d'une maladie ou affection à médiation par fxr, telle que la cirrhose biliaire primitive (pbc), la cholangite sclérosante primitive (
MA40814A 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée MA40814A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113134P 2015-02-06 2015-02-06
PCT/US2016/016694 WO2016127019A2 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Publications (1)

Publication Number Publication Date
MA40814A1 true MA40814A1 (fr) 2019-08-30

Family

ID=56564878

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40814A MA40814A1 (fr) 2015-02-06 2016-02-05 Compositions pharmaceutiques pour thérapie combinée

Country Status (31)

Country Link
US (3) US11311557B2 (fr)
EP (2) EP4035665A1 (fr)
JP (2) JP7306791B2 (fr)
KR (1) KR20170115071A (fr)
CN (1) CN107405325B (fr)
AR (1) AR103624A1 (fr)
AU (2) AU2016215179B2 (fr)
BR (1) BR112017016766B1 (fr)
CA (1) CA2976056C (fr)
CL (3) CL2017001983A1 (fr)
CO (1) CO2017007959A2 (fr)
CR (1) CR20170356A (fr)
DK (1) DK3253382T3 (fr)
EA (1) EA036404B1 (fr)
EC (1) ECSP17057848A (fr)
ES (1) ES2905872T3 (fr)
GT (1) GT201700174A (fr)
HK (1) HK1246191A1 (fr)
IL (2) IL253719B (fr)
MA (1) MA40814A1 (fr)
MX (1) MX2017010131A (fr)
NI (1) NI201700100A (fr)
PE (1) PE20180027A1 (fr)
PH (1) PH12017501384A1 (fr)
SG (1) SG11201706347SA (fr)
SV (1) SV2017005512A (fr)
TN (1) TN2017000344A1 (fr)
TW (1) TW201628625A (fr)
UA (1) UA125744C2 (fr)
WO (1) WO2016127019A2 (fr)
ZA (1) ZA201706007B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
ES2974281T3 (es) * 2015-04-07 2024-06-26 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
EP4233910A3 (fr) * 2016-03-31 2024-01-17 Genfit Méthodes de traitement de maladies cholestatiques
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
US20200054589A1 (en) * 2017-02-21 2020-02-20 Genfit Combination of a ppar agonist with a fxr agonist
CN111093705A (zh) * 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
KR20210150436A (ko) * 2019-04-10 2021-12-10 장피트 화학식 (i)의 화합물 및 glp-1 수용체 효현제를 포함하는 병용 요법
JP2022536060A (ja) * 2019-05-30 2022-08-12 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物
CN110287493B (zh) * 2019-06-28 2023-04-18 中国科学技术信息研究所 风险短语识别方法、装置、电子设备及存储介质
MX2022000742A (es) * 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
JP2022548725A (ja) * 2019-09-20 2022-11-21 レネオ ファーマシューティカルズ，インク． 腎臓病の治療におけるｐｐａｒデルタアゴニストの使用
US20220387467A1 (en) * 2019-11-22 2022-12-08 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN112885471B (zh) * 2021-03-12 2023-01-24 上海中医药大学附属岳阳中西医结合医院 基于贝叶斯网络最大熵自学习扩展集对分析的银屑病疗效评价系统
WO2023147141A1 (fr) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Polythérapie
WO2024132001A1 (fr) * 2022-12-21 2024-06-27 Charles University, Faculty Of Pharmacy In Hradec Kralove Ligands de récepteurs nucléaires multicibles à base d'acide 2-(4-(quinolin-2-yloxy)phénoxy)propanoïque et d'acide 2-(4-(quinoxalin-2-yloxy)phénoxy)propanoïque pour le traitement de maladies métaboliques et hépatiques

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (fr) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
FI52570C (fi) 1969-04-16 1977-10-10 Sumitomo Chemical Co Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
AT296986B (de) 1969-08-13 1972-03-10 Merz & Co Verfahren zur Herstellung von neuen α-Halogenphenoxy-isobutyroyl-β-nicotinoyl-glykolen
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
JPS5118954B2 (fr) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (de) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkancarbonsäureester von Oxyalkyltheophyllinen, Verfahren zu ihrer Herstellung und Arzneimittel
FR2244511B1 (fr) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
DE69329894T2 (de) 1992-12-08 2001-05-03 Ss Pharmaceutical Co., Ltd. Arylamidderivate
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2001509165A (ja) * 1997-01-24 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バリヤ機能の回復、表皮の分化の促進及び増殖の抑制のためのＦＸＲ、ＰＰＡＲα及びＬＸＲαの活性剤の使用
YU2700A (sh) * 1997-08-29 2002-06-19 Pfizer Products Inc. Farmaceutska kombinacija koja obuhvata amlodipin i statin jedinjenja
MXPA00004036A (es) 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Compuestos triciclicos novedosos y su uso en medicina; proceso para su preparacion y composiciones farmaceuticas que los contienen..
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
CA2355820A1 (fr) 1998-12-18 2000-06-29 Abbott Laboratories Formulations comprenant des liporegulateurs
EP1140079B1 (fr) 1998-12-23 2009-06-03 Glaxo Group Limited Methodes de titrage de ligands de recepteurs nucleaires
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US6071955A (en) 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
CA2406067A1 (fr) 2000-04-19 2001-11-01 Thomas Julius Borody Compositions comprenant la combinaison d'un acide biliaire et d'un fibrate pour utilisation dans des therapies contre les troubles associes a l'hyperlipidemie
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
ES2233700T3 (es) 2000-09-18 2005-06-16 Glaxo Group Limited Derivados de aminopropoxiarilo sustituidos utiles como agonistas para lxr.
CA2440680C (fr) 2001-03-12 2010-06-01 Roberto Pellicciari Steroides comme agonistes de fxr
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (fr) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Nouveau agonist steroidal pour FXR
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
PL1734970T3 (pl) 2004-03-12 2015-05-29 Intercept Pharmaceuticals Inc Leczenie zwłóknienia z zastosowaniem ligandów FXR
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060252670A1 (en) * 2004-10-14 2006-11-09 Intercept Pharmaceuticals Inc. Method of reducing drug-induced adverse side effects in a patient
WO2006121861A2 (fr) 2005-05-05 2006-11-16 Microbia, Inc. Inhibiteurs d'absorption de biphenylazetidinone cholesterol
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
AU2007215207A1 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US20070197606A1 (en) 2006-02-22 2007-08-23 Burczynski Frank J Use of ppar agonists as anti-oxidants
CN101534641A (zh) * 2006-03-22 2009-09-16 哈佛大学校长及研究员协会 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
BRPI0711875A2 (pt) 2006-05-24 2012-01-10 Lilly Co Eli compostos e métodos para modular os fxr
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
WO2008002573A2 (fr) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr
BRPI0621942A2 (pt) 2006-08-04 2011-10-18 Aska Pharm Co Ltd preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação
EP1886685A1 (fr) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
EP1894928A1 (fr) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Composes heterocycliques de liaison au fxr
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
WO2008039829A2 (fr) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Inhibiteurs de l'absorption de cholestérol de diphénylhétérocycle
CL2007003035A1 (es) * 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
EP2289883A1 (fr) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Nouveaux composés modulant l'activité du recepteur FXR (NR1H4)
KR101962209B1 (ko) * 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
AU2013277429B2 (en) 2012-06-19 2016-01-14 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
BR112015009395A2 (pt) 2012-10-26 2017-07-04 Intercept Pharmaceuticals Inc processo para preparação de derivados do ácido biliar
BR112015028399B1 (pt) * 2013-05-14 2021-11-16 Intercept Pharmaceuticals, Inc Derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x, composição farmacêutica e uso dos referidos derivados
US10077268B2 (en) * 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
DK3253382T3 (da) 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi

Also Published As

Publication number Publication date
US20220280533A1 (en) 2022-09-08
PH12017501384A1 (en) 2018-01-08
WO2016127019A3 (fr) 2016-11-03
EP4035665A1 (fr) 2022-08-03
EP3253382B1 (fr) 2021-11-17
SG11201706347SA (en) 2017-09-28
EP3253382A2 (fr) 2017-12-13
EP3253382A4 (fr) 2018-10-31
WO2016127019A2 (fr) 2016-08-11
CN107405325B (zh) 2021-11-12
CL2018003604A1 (es) 2019-02-22
DK3253382T3 (da) 2022-02-14
EA036404B1 (ru) 2020-11-06
EA201791770A1 (ru) 2017-12-29
PE20180027A1 (es) 2018-01-09
US20180008616A1 (en) 2018-01-11
AU2016215179A1 (en) 2017-08-24
AU2016215179B2 (en) 2021-02-25
US11311557B2 (en) 2022-04-26
ES2905872T3 (es) 2022-04-12
SV2017005512A (es) 2018-06-12
JP2022000483A (ja) 2022-01-04
AR103624A1 (es) 2017-05-24
UA125744C2 (uk) 2022-06-01
BR112017016766B1 (pt) 2023-11-07
TN2017000344A1 (en) 2019-01-16
KR20170115071A (ko) 2017-10-16
JP2018504438A (ja) 2018-02-15
CL2018001006A1 (es) 2018-06-15
CL2017001983A1 (es) 2018-04-20
IL253719B (en) 2022-04-01
IL290823A (en) 2022-04-01
TW201628625A (zh) 2016-08-16
US20220280534A1 (en) 2022-09-08
ECSP17057848A (es) 2017-10-31
CR20170356A (es) 2018-02-28
GT201700174A (es) 2018-11-13
CA2976056C (fr) 2024-02-06
MX2017010131A (es) 2017-11-01
BR112017016766A2 (pt) 2018-04-10
CO2017007959A2 (es) 2017-10-31
JP7306791B2 (ja) 2023-07-11
ZA201706007B (en) 2019-01-30
NI201700100A (es) 2018-09-06
CA2976056A1 (fr) 2016-08-11
HK1246191A1 (zh) 2018-09-07
IL253719A0 (en) 2017-09-28
CN107405325A (zh) 2017-11-28
AU2021201015A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA46990B1 (fr) Compositions glp-1 et ses utilisations
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA40290A1 (fr) Agents immunorégulateurs
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2020006957A (es) Composicion de liberacion modificada que comprende un cannabinoide.
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MX2022002183A (es) Composiciones de éster de ácido cannabinoide y sus usos.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA38699A1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
MA39319A1 (fr) Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA61742A1 (fr) Composition pharmaceutique aqueuse d'anticorps anti pd-1 prolgolimab et son utilisation
BR112018003392A2 (pt) composição farmacêutica compreendendo um inibidor da hmg-coa redutase e um inibidor eca
MA41102A (fr) Compositions contenant de la curcumine à biodisponibilité améliorée
WO2019221177A9 (fr) Médicament prophylactique et/ou thérapeutique contre la dépendance
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA43507B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA53977B1 (fr) Compositions stables du sémaglutide et leurs utilisations